Edwards Lifesciences, Inc. EW presented results from ... continued excellent outcomes for patients treated with the Edwards SAPIEN valve platform. The data were published in the Journal of the ...

Executives expect a new label indication and a hoped-for easing of hospital capacity constraints to accelerate sales this year.

Edwards Lifesciences Corporation (EW)'s share was ... The introduction of the Sapien X4 valve generation and the expected approval of Early TAVR for asymptomatic patients by mid-2025 will likely ...

Edwards Lifesciences’ EW fourth-quarter performance ... the increasing global uptake of SAPIEN portfolio is highly encouraging. Meanwhile, a volatile macro economy and adverse currency impacts ...

Edwards Lifesciences has come to dominate surgical ... Edwards has established itself as the leader in the TAVR franchise, with its Sapien product which is primarily delivered either through ...

Delays in regulatory approvals for new products like SAPIEN M3 or potential changes to reimbursement policies could affect adoption rates. Edwards Lifesciences concluded 2024 with strong financial ...

These statements speak only as of the date on which they were made, and Edwards does not undertake ... and the impact of early intervention with SAPIEN. The trial results demonstrated superior ...

Edwards Lifesciences is likely to have witnessed continued growth in procedures across the United States and worldwide. Continued strong demand for the company’s SAPIEN platform is expected to ...

Q4 TMTT sales grew 88% to $105 million with increasing contribution to Edwards' growth Q4 EPS of $0.58 1; adjusted 2 EPS of $0.59, driven by strong top-line performance Presented results of two ...

“It was a year of meaningful progress for Edwards in 2024, as our 16,000 employees advanced life-saving structural heart innovations for patients around the world. We exited the year in a strong ...